Clinical Trial of YH32364 in Patients With Locally Advanced or Metastatic EGFR Overexpressing Solid Tumors
Trial statusRecruiting
Trial phasePhase 1, Phase 2
Trial typeInterventional
Biological sexAll
Age18+
SponsorYuhan Corporation
About this trial
This is a study for people with locally advanced or metastatic cancer for whom previous treatment was not successful. Adults aged 18 and over with advanced cancer with Epidermal Growth Factor Receptor (EGFR) overexpressing can join the study. The purpose of this study is to find out whether a medicine called YH32364 helps people with locally advanced or metastatic cancers with EGFR overexpression.
Eligibility criteria
Qualifiers
Must sign an informed consent form (ICF) prior to any study specific procedures
ECOG performance status 0 or 1
Estimated life expectancy of at least 3 months
A woman must not be breastfeeding
Disqualifiers
Known uncontrolled central nervous system (CNS) metastases, spinal cord compression, and/or carcinomatous meningitis
Have history of a second primary cancer with the exception of
curatively treated non-melanomatous skin cancer
curatively treated cervical or breast carcinoma in situ, or
Trial design
Treatments tested in this trial
- YH32364
Treatment groups
80 Participants
are divided into 1 treatment groupLocations
4Korea University Anam Hospital02841, Seoul South Korea
Samsung Medical Center06351, Seoul South Korea
Seoul National University Hospital03080, Seoul South Korea
Severance Hospital03722, Seoul South Korea
Sponsors and collaborators
Yuhan Corporation
Lead sponsor
Source ClinicalTrials.gov